Agenus Inc. Pleased to have Agenus with us. This is especially the case for companies that receive approval for treatments for more widespread diseases like depression, Alzheimer’s, obesity, diabetes, arthritis and the most dreaded of all – cancer. The positive opinion signals that Mosquirix meets the necessary quality, safety and efficacy requirements according to EU standards. This co-primary endpoint is based on predefined criterion that was agreed upon by regulatory authorities. Further, more than a third of these patients remain alive for more than three years from initial treatment, and more than 80% of these have not progressed. At this time, the safety profile of HZ/su in older adults is based on data from more than 440 subjects who received HZ/su in phase I and II clinical trials.
Dr. Data from Phase 3 pivotal trials of four GSK vaccine candidates, which include MAGEA3 Cancer immunotherapeutic (CI) for selected patients with non-small cell lung cancer, and melanoma, RTS,S for malaria, and Herpes Zoster for shingles, are anticipated to be released over the next year or so. He stated, “We are pretty confident that melanoma would be out this year, perhaps in coming months. SECANT allows rapid generation of soluble, full-length human antibodies. The trial, launched in 2009 and concluded in January 2014, enrolled 15,459 young child (5-17 months) and infant (6-12 weeks) participants. About the ZOE-70 trial The ZOE-70 (ZOster Efficacy in adults aged 70 years and over) study is a randomised, observer-blind, placebo-controlled (saline solution) multicentre, multinational (North America, Europe, Latin America, Asia-Pacific) phase III trial involving more than 14,800 adults aged 70 years and older. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen Sciences Ireland UC and includes several candidates in Phase 2, as well as shingles and malaria vaccines which have successfully completed Phase 3 clinical trials.
Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Spectrum Pharmaceuticals, and IntelGenx Technologies. This press release contains forward-looking statements, including statements regarding the Company’s upcoming corporate presentation. More important than gossip about takeover is the mere current scientific and potential promising reality of Agenus vaccines in clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Agenus is an immunology company developing a series of Checkpoint Modulators for the treatment of patients with cancer, infectious diseases, and other immune disorders, heat shock protein (HSP)-based vaccines, and immune adjuvants. This acquisition will initially provide Agenus with two leading-edge checkpoint antibody programs targeting GITR and OX40, four additional undisclosed programs, and a discovery platform to mine numerous additional antibodies. Cancer can highjack control of these receptors and block the T-cell response to cancer, which creates tolerance of the immune system to cancer.